Live Quote · NASDAQINKTHealthcare· Biotechnology

MiNK Therapeutics, Inc.

$11.67 1.83%(+$0.21)
TickerSpark Score
53/100
Mixed
80
Valuation
40
Profitability
20
Growth
76
Health
50
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INKT research report →

52-Week Range7% of range
Low
$7.01
Current
$11.67
High
$76.00
Company Overviewminktherapeutics.com

About the company

MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies.

CEO
Jennifer S. Buell
IPO
2021
Employees
23
HQ
New York City, NY, US

Price Chart

+62.76% · this period
$64.17$35.59$7.01Jul 02Dec 31Jul 02
Valuation
Market Cap
$58.14M
P/E
-4.12
P/S
0.00
P/B
-4.41
EV/EBITDA
-3.95
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
76.02%
ROIC
-415.48%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-12,494,260 · -15.85%
EPS
$-2.93 · -1.03%
Op Income
$-12,487,304
FCF YoY
37.99%
Performance & Tape
52W High
$76.00
52W Low
$7.01
50D MA
$11.53
200D MA
$12.06
Beta
0.47
Avg Volume
40.57K

Get TickerSpark's AI analysis on INKT

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 4, 26Ryan Barbarasell500
Jun 4, 26Ryan Barbarasell1,000
Jun 1, 26Holcomb John Bradleyother1,091
Mar 2, 26Holcomb John Bradleyother1,239
Jun 1, 26Ryan Barbaraother1,434
Mar 2, 26Ryan Barbaraother1,629
Jun 1, 26Corvese Brianother1,444
Mar 2, 26Corvese Brianother1,640
Jun 1, 26Behner Peterother1,313
Mar 2, 26Behner Peterother1,491
Coverage · INKT

Our INKT coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on INKT yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate INKT report →
Internal Compare

Similar companies

Peers in the same neighborhood.